import { EducationalContent } from '../types';

export const medicationAssistedTreatmentContent: EducationalContent = {
  id: 'medication-assisted-treatment',
  title: 'Medication-Assisted Treatment (MAT)',
  category: 'Addiction Medicine',
  subcategory: 'Opioids',
  description: 'Evidence-based medications for opioid use disorder and how they support recovery',
  levels: [
    {
      level: 1,
      title: 'Introduction to MAT',
      content: `# Introduction to Medication-Assisted Treatment (MAT)

## What is MAT?

**Medication-Assisted Treatment (MAT)** is the use of FDA-approved medications, combined with counseling and behavioral therapies, to treat substance use disorders.

For opioid use disorder, MAT involves using medications that:
- Reduce withdrawal symptoms
- Reduce cravings
- Block the effects of opioids
- Allow people to focus on recovery

## Why Use Medications for Addiction?

**Addiction is a medical condition:**
- Affects brain chemistry
- Causes physical changes
- Is not a moral failing
- Deserves medical treatment

**Medications help by:**
- Treating the biology of addiction
- Reducing withdrawal and cravings
- Allowing focus on recovery
- Improving chances of success

## Three FDA-Approved Medications

### Methadone

**What it is:**
- Long-acting opioid medication
- Given daily in specialized clinics
- Prevents withdrawal and reduces cravings
- Used for over 50 years

**How it works:**
- Activates opioid receptors
- Prevents withdrawal
- Reduces cravings
- Blocks euphoria from other opioids

### Buprenorphine

**What it is:**
- Partial opioid agonist
- Given in office or clinic settings
- Taken at home (after stabilization)
- Newer than methadone

**How it works:**
- Partially activates opioid receptors
- Prevents withdrawal
- Reduces cravings
- Has ceiling effect (safer)

### Naltrexone

**What it is:**
- Opioid blocker
- Monthly injection or daily pill
- Must be opioid-free first
- Blocks opioid effects

**How it works:**
- Blocks opioid receptors
- No opioid effect
- Blocks euphoria from opioids
- No physical dependence

## How MAT Helps

**Reduces withdrawal:**
- No physical sickness
- Can function normally
- Can engage in treatment

**Reduces cravings:**
- Less urge to use opioids
- Can focus on recovery
- Improves quality of life

**Blocks effects:**
- Can't get high from opioids
- Reduces relapse risk
- Helps maintain abstinence

**Lowers mortality:**
- 50% or more reduction in overdose deaths
- Reduces disease transmission
- Improves overall health

## Common Myths vs. Facts

| Myth | Fact |
|------|-------|
| "MAT is trading one addiction for another" | MAT treats addiction with medications, like other medical conditions |
| "You're not really in recovery if on MAT" | Recovery is about health and function, not abstinence from medications |
| "MAT should be short-term" | Long-term treatment often works best |
| "MAT is a crutch" | MAT treats brain disease, like insulin for diabetes |

## MAT is Most Effective When Combined

\`\`\'
Medications
    ↓
+
Counseling/Behavioral therapy
    ↓
+
Recovery support
    ↓
=
Best outcomes
\`\`\`

## Who Can Benefit from MAT?

**Anyone with opioid use disorder:**
- Prescription opioid problems
- Heroin use
- Fentanyl exposure
- Any opioid addiction

**Benefits are greatest when:**
- Started as early as possible
- Combined with counseling
- Continued long enough
- Individualized to patient needs

## The Benefits of MAT

**For individuals:**
- 50%+ reduction in mortality
- Reduced opioid use
- Improved retention in treatment
- Better social functioning
- Reduced criminal activity
- Improved employment
- Better overall health

**For communities:**
- Reduced overdose deaths
- Reduced disease transmission
- Reduced criminal justice involvement
- Healthcare cost savings
- More productive community members

## Is MAT Right for Everyone?

**MAT is appropriate for most people with OUD, but:**
- Individual choice matters
- Medical history considered
- Pregnancy requires special approach
- Other health conditions considered
- Patient preferences respected

**Not for:**
- People who don't want it (motivation matters)
- People unable to take medications for medical reasons

## Getting Started with MAT

**Steps:**
1. **Find a provider**
   - OTP (for methadone)
   - Waivered provider (for buprenorphine)
   - Any provider (for naltrexone)

2. **Evaluation**
   - Assessment of OUD
   - Medical evaluation
   - Treatment planning

3. **Induction**
   - Starting medication
   - Finding right dose
   - Stabilization

4. **Maintenance**
   - Ongoing medication
   - Counseling
   - Recovery support

5. **Recovery**
   - Health improvements
   - Life changes
   - Ongoing support

## Remember

**MAT:**
- Saves lives
- Is evidence-based
- Is standard of care
- Treats a medical condition
- Supports recovery
- Offers hope

**Recovery is possible with MAT!`,

      keyPoints: [
        'MAT uses FDA-approved medications to treat opioid use disorder',
        'Three medications: methadone, buprenorphine, and naltrexone',
        'MAT reduces mortality by 50% or more',
        'MAT is most effective when combined with counseling'
      ],
      vocabulary: [
        { term: 'MAT', definition: 'Medication-Assisted Treatment - use of medications for SUD treatment' },
        { term: 'Methadone', definition: 'Long-acting opioid medication for OUD treatment' },
        { term: 'Buprenorphine', definition: 'Partial opioid agonist medication for OUD treatment' },
        { term: 'Naltrexone', definition: 'Opioid antagonist medication that blocks opioid effects' }
      ]
    },
    {
      level: 2,
      title: 'Methadone and Buprenorphine',
      content: `# Methadone and Buprenorphine for OUD Treatment

## Overview

**Methadone and buprenorphine are:**
- The most common MAT medications
- Opioid agonists (full or partial)
- Proven to reduce mortality and improve outcomes
- First-line treatments for OUD

## Methadone

### What is Methadone?

**A full opioid agonist:**
- Synthetic opioid medication
- Long-acting (24-36 hours)
- Used for OUD treatment since 1960s
- Most proven track record

### How Methadone Works

\`\`\`
Methadone → Activates opioid receptors
    ↓
Prevents withdrawal symptoms
    ↓
Reduces cravings
    ↓
Blocks euphoria from other opioids (at stable dose)
    ↓
At therapeutic doses, no euphoria
\`\`\`

### Effectiveness

**Evidence:**
- Reduces mortality by 50% or more
- Retains patients in treatment
- Reduces illicit opioid use
- Improves social functioning
- Reduces criminal activity
- Reduces disease transmission (HIV, hepatitis)

### Dosing

**Induction/Stabilization:**
\`\`\'
Starting dose: 10-30mg (based on assessment)
    ↓
Observe for 2-4 hours
    ↓
Additional dose if withdrawal persists
    ↓
Daily adjustments
    ↓
Stabilization: 60-120mg typical
    ↓
Individualized (some need higher, some lower)
\`\`\'

**Maintenance:**
- Daily dosing
- Take-home doses possible for stable patients
- Long-term treatment recommended

### Dispensing

**Opioid Treatment Programs (OTPs):**
- Specialized clinics licensed to provide methadone
- Daily dispensing initially
- Observed dosing
- Take-home doses as patient progresses

**Take-home schedule (federal guidelines):**
- Stable for 1 year: up to 6 take-homes/month
- Stable for 2 years: up to 2 weeks
- Stable for 3 years: up to 1 month

### Benefits

**Proven benefits:**
- Most evidence of all MAT medications
- Highly effective at reducing illicit use
- Daily structure and monitoring
- Take-home doses reward stability
- Low cost (compared to street opioids)

### Side Effects

**Common:**
- Constipation
- Sweating
- Weight gain
- Sexual dysfunction
- Menstrual irregularities
- Drowsiness (initially)
- QT prolongation (heart rhythm)

### Risks

**Medical risks:**
- Respiratory depression (especially when starting)
- QT prolongation (heart rhythm)
- Drug interactions
- Diversion potential

### Contraindications

**Absolute:**
- Severe respiratory insufficiency
- Severe uncontrolled asthma
- Untreated sleep apnea

**Caution:**
- Liver disease
- Kidney disease
- Heart conditions (QT prolongation)
- Pregnancy (discuss benefits vs. risks)
- Other medications (interactions)

### Special Populations

**Pregnancy:**
- Treatment of choice for OUD in pregnancy
- Buprenorphine also an option
- Methadone has longer track record
- Coordination with prenatal care essential

**Hepatitis/HIV:**
- Can be used
- Monitor liver function
- May need dose adjustment

**Adolescents:**
- Requires specialized program
- Higher monitoring
- Usually buprenorphine preferred

## Buprenorphine

### What is Buprenorphine?

**A partial opioid agonist:**
- Activates opioid receptors partially
- Has a "ceiling effect"
- Less respiratory depression risk
- Available since 2002 for OUD

### How Buprenorphine Works

\`\`\`
Buprenorphine → Partially activates opioid receptors
    ↓
Prevents withdrawal symptoms
    ↓
Reduces cravings
    ↓
Blocks other opioids at higher doses
    ↓
Ceiling effect on respiratory depression
    ↓
No euphoria at therapeutic doses
\`\`\`

**The ceiling effect:**
\`\`\'
As dose increases, effect plateaus
    ↓
No additional respiratory depression
    ↓
Safer than methadone in overdose
\`\`\`

### Formulations

**Sublingual (under tongue):**
- Suboxone (buprenorphine + naloxone)
- Subutex (buprenorphine only)
- Zubsolv
- Generic options

**Bunavail (buccal - inside cheek):**
- Alternative to sublingual

**Extended-release:**
- Sublocade (monthly injection)
- Brixadi (weekly/monthly injection)

**Implant:**
- Probuphine (6-month implant)

### Dosing

**Induction:**
\`\`\'
IMPORTANT: Must be in withdrawal first (COWS ≥ 8)
    ↓
Day 1: 2-8mg (may repeat after 1-2 hours)
    ↓
Day 1 total: up to 16mg
    ↓
Day 2: Assess, adjust based on symptoms
    ↓
Stabilization: 8-24mg typical
\`\`\'

**Maintenance:**
- Once stable, daily or divided dosing
- Some formulations allow weekly or monthly dosing
- Long-term treatment recommended

### Office-Based Treatment

**DATA-Waiver (X-waiver):**
- Providers need waiver to prescribe
- Can prescribe in office setting
- More accessible than methadone
- No specialized clinic needed

**Benefits:**
- Privacy
- Accessibility
- Integration with primary care
- Flexible scheduling
- Take-home from day 1 after induction

### Benefits

**Advantages:**
- Office-based treatment
- Ceiling effect (safer)
- Take-home from day 1
- Good safety profile
- Less stigma than methadone
- Can be prescribed by any waivered provider

### Side Effects

**Common:**
- Headache
- Nausea
- Constipation
- Insomnia
- Sweating

### Risks

**Medical risks:**
- Precipitated withdrawal if started too early
- Drug interactions
- Hepatotoxicity at high doses
- Diversion potential (less than methadone)

### Contraindications

**Absolute:**
- Severe respiratory insufficiency

**Caution:**
- Liver disease
- Kidney disease
- Pregnancy (discuss)
- Breastfeeding (generally safe)

### Special Populations

**Pregnancy:**
- Alternative to methadone
- Appears safe
- May cause less severe NAS than methadone
- Coordination with prenatal care

**Adolescents:**
- Approved for ages 16+
- Office-based treatment appropriate
- Family involvement

**Hepatitis:**
- Safer profile than methadone
- Monitor liver function

## Comparing Methadone vs. Buprenorphine

| Factor | Methadone | Buprenorphine |
|--------|-----------|---------------|
| Type | Full agonist | Partial agonist |
| Setting | OTP only | OTP + office |
| Daily visits required | Initially | No (after induction) |
| Take-home doses | Possible with stability | Yes (after induction) |
| Can start immediately | Yes | Must be in withdrawal |
| Overdose risk | Higher | Lower (ceiling effect) |
| Diversion potential | Yes | Lower |
| Evidence base | Extensive (50+ years) | Good (20+ years) |
| Pregnancy | Preferred | Alternative |
| Hepatitis | Use caution | Safer profile |
| Induction | Easy | More challenging |
| Stigma | Higher | Lower |

## Choosing Between Methadone and Buprenorphine

**Factors to consider:**

\`\`\'
Patient preference
    ↓
Pregnant? → Methadone preferred, buprenorphine alternative
    ↓
Liver disease? → Buprenorphine preferred
    ↓
Need for daily structure? → Methadone
    ↓
Need privacy/flexibility? → Buprenorphine
    ↓
Previous treatment response? → Try what worked or different
    ↓
Practical considerations (cost, location, access)
\`\`\'

**Both are effective options - choice should be individualized**`,

      keyPoints: [
        'Methadone and buprenorphine are first-line treatments for OUD',
        'Methadone is a full agonist, buprenorphine is a partial agonist',
        'Both reduce mortality and improve outcomes',
        'Choice depends on patient factors and preferences'
      ],
      vocabulary: [
        { term: 'Agonist', definition: 'Medication that activates opioid receptors' },
        { term: 'Partial Agonist', definition: 'Medication that partially activates opioid receptors with ceiling effect' },
        { term: 'OTP', definition: 'Opioid Treatment Program - specialized methadone clinic' },
        { term: 'DATA-Waiver', definition: 'Required training for providers to prescribe buprenorphine' }
      ]
    },
    {
      level: 3,
      title: 'Naltrexone and Extended-Release Formulations',
      content: `# Naltrexone and Extended-Release MAT

## Naltrexone for OUD

### What is Naltrexone?

**An opioid antagonist:**
- Blocks opioid receptors
- Prevents opioids from having effect
- No opioid activity
- No physical dependence potential

### How Naltrexone Works

\`\`\'
Naltrexone → Binds to and blocks opioid receptors
    ↓
Cannot be displaced by other opioids
    ↓
Opioids cannot activate receptors
    ↓
No euphoria from opioids
    ↓
If use opioids while on naltrexone, no effect
\`\`\`

**Mechanism:**
- Competitive antagonist
- Binds to mu-opioid receptors
- Blocks effects of heroin, prescription opioids
- Blocks effects of methadone and buprenorphine

### Formulations

**Oral naltrexone:**
- 50mg once daily
- Poor adherence (significant problem)
- Rarely used for OUD
- Mostly used for alcohol use disorder

**Injectable naltrexone (Vivitrol):**
- 380mg intramuscular injection
- Given monthly
- Blocks opioids for 4 weeks
- Better adherence than oral

### Effectiveness

**When taken as directed:**
- Blocks opioid effects
- Reduces craving in some
- Helps maintain abstinence
- No euphoria from opioids (no reinforcement)

**Evidence:**
- Poor oral adherence
- Injectable more effective
- Compared to methadone/buprenorphine:
  - Less effective at retaining patients
  - Similar efficacy when adhered to
  - Different patient population

### Induction

**The challenge:**
\`\`\'
Must be completely opioid-free first
    ↓
No opioids for 7-10 days
    ↓
No withdrawal symptoms
    ↓
Then give naltrexone
\`\`\'

**Why:**
- Starting too early causes precipitated withdrawal
- Must have cleared all opioids from system
- Short-acting opioids: 7-10 days
- Long-acting opioids: 10-14 days

**Induction challenges:**
- Getting patients opioid-free
- Managing withdrawal during wait period
- Risk of relapse during induction
- Motivation required

### Dosing

**Oral:**
- 50mg once daily
- Poor adherence limits use

**Injectable (Vivitrol):**
\`\`\'
Must be opioid-free for 7-10 days
    ↓
First dose: 380mg IM gluteal
    ↓
Repeat monthly
\`\`\'

**Administration:**
- Gluteal injection (buttock)
- Given in healthcare setting
- Monthly visits
- No take-home medication

### Benefits

**Advantages:**
- No opioid agonist effects
- No physical dependence
- No abuse potential
- No diversion risk
- Once monthly (injectable)
- No daily medication (injectable)
- Can be prescribed by any provider

**For patients who:**
- Want to avoid opioid medications
- Are highly motivated
- Have completed withdrawal
- Have good support
- Want monthly dosing

### Side Effects

**Common:**
- Injection site pain (injectable)
- Nausea
- Headache
- Dizziness
- Fatigue
- Muscle cramps

**Risk:**
- Opioid overdose if relapse after stopping
- Loss of tolerance
- Higher overdose risk if use opioids

### Contraindications

**Absolute:**
- Acute hepatitis
- Liver failure
- Current opioid use (must be opioid-free)
- Opioid dependence (must be withdrawn first)

**Caution:**
- Liver disease
- Kidney disease
- Pregnancy
- Bleeding disorders (injectable)

### Special Populations

**Pregnancy:**
- Not recommended
- Insufficient data
- Risks vs. benefits discussion

**Adolescents:**
- Evidence limited
- Consider in motivated patients
- Complete withdrawal required first

**People with pain:**
- Cannot receive pain relief from opioids
- Need alternative pain management
- Consider before prescribing

### Overdose Risk After Relapse

**Major concern:**
\`\`\'
On naltrexone → Blocked opioids, no effect
    ↓
Stop naltrexone → Tolerance has decreased
    ↓
Use previous opioid dose → Overdose risk
\`\`\'

**Education critical:**
- Warn patients about decreased tolerance
- Explain overdose risk
- Encourage not to use opioids
- If use opioids, use tiny amounts

## Extended-Release Buprenorphine

### Sublocade (Monthly Injection)

**Description:**
- Buprenorphine monthly injection
- 300mg first month, then 100-300mg monthly
- SC or IM administration
- Continuous buprenorphine release

**Induction:**
- Must be stabilized on sublingual buprenorphine first
- Can convert from oral buprenorphine
- Must be on ≤ 24mg sublingual buprenorphine

**Benefits:**
- Monthly dosing
- No take-home doses
- No diversion
- Consistent medication levels
- Good for patients with adherence issues

**Side effects:**
- Injection site pain
- Constipation
- Headache
- Nausea
- Insomnia

### Brixadi (Weekly/Monthly Injection)

**Description:**
- Extended-release buprenorphine
- Weekly or monthly injections
- Can be used for induction (monthly)
- Newer formulation

**Benefits:**
- Flexible dosing
- Can be used for induction
- Weekly or monthly options
- No take-home doses

### Probuphine (Implplant)

**Description:**
- 4 subdermal implants
- Each implant: 80mg buprenorphine
- Total: 320mg
- Lasts 6 months

**Procedure:**
- Minor office procedure
- Local anesthesia
- Inserted in upper arm
- Removed after 6 months

**Candidates:**
- Stable on buprenorphine 8mg or less
- No need for dose adjustments
- Motivated for maintenance
- Good candidates for long-term treatment

**Benefits:**
- 6 months of treatment
- No daily dosing
- No take-home doses
- No diversion
- Consistent levels

**Risks:**
- Surgical procedure
- Implant site reactions
- Extrusion
- Infection
- Not adjustable

## Choosing the Right Medication

### Decision Framework

\`\`\'
Patient wants medication
    ↓
Pregnant?
    YES → Methadone (preferred) or Buprenorphine
    NO  → Continue

    ↓
Wants to avoid all opioids?
    YES → Naltrexone (if able to complete withdrawal)
    NO  → Continue

    ↓
Needs structure or high doses?
    YES → Methadone
    NO  → Continue

    ↓
Wants office-based treatment, flexibility?
    YES → Buprenorphine
    NO  → Methadone

    ↓
Adherence issues?
    YES → Extended-release formulation
    NO  → Continue as chosen
\`\`\'

### Patient Factors

| Factor | Favors Methadone | Favors Buprenorphine | Favors Naltrexone |
|--------|------------------|---------------------|-------------------|
| Pregnancy | Preferred | Alternative | Avoid |
| Liver disease | Use caution | Safer | Avoid |
| Wants office-based | No | Yes | Any provider |
| Wants to avoid opioids | No | Partial | Yes |
| Needs structure | Yes | Maybe | No |
| Highly motivated | Any | Any | Yes |
| Good support | Any | Any | Important |
| Completed withdrawal | Any | Any | Required |
| Chronic pain | Maybe helps | Maybe helps | No pain relief |
| Adherence problems | Daily observed | Consider XR | Consider XR |

## Switching Between Medications

### Methadone to Buprenorphine

**Challenging transition:**
\`\`\'
Reduce methadone to 30-40mg or less
    ↓
Wait 24-48 hours (until in withdrawal)
    ↓
Induce buprenorphine
    ↓
Monitor for precipitated withdrawal
\`\`\'

### Buprenorphine to Methadone

**Simpler:**
- Stop buprenorphine
- Wait 24-48 hours
- Start methadone
- Regular induction

### To Naltrexone

**From either:**
- Must complete withdrawal
- 7-10 days opioid-free
- Monitor for withdrawal
- Then start naltrexone

## Duration of Treatment

### How Long Should Treatment Continue?

**General principles:**
- Minimum 12 months to assess effectiveness
- Longer treatment for most patients
- Many patients benefit from years of treatment
- Some benefit from lifelong treatment
- Individualize to patient

**Premature tapering:**
- High relapse risk
- Should be patient-driven
- Should be slow
- Should be to stable life situation

**When to consider tapering:**
- Stable recovery (12+ months)
- Patient preference
- Stable life situation
- Good support system
- Understanding relapse risk

**How to taper:**
- Very slow (months to years)
- Monitor for withdrawal and cravings
- Restart if relapse occurs
- Not right for everyone`,

      keyPoints: [
        'Naltrexone is an opioid antagonist that blocks opioid effects',
        'Naltrexone requires being completely opioid-free before starting',
        'Extended-release formulations improve adherence',
        'Choice of medication depends on patient factors and preferences'
      ],
      vocabulary: [
        { term: 'Antagonist', definition: 'Medication that blocks opioid receptors' },
        { term: 'Precipitated Withdrawal', definition: 'Sudden, severe withdrawal caused by antagonist medication' },
        { term: 'Extended-Release', definition: 'Long-acting medication formulation released over time' },
        { term: 'Vivitrol', definition: 'Brand name extended-release injectable naltrexone' }
      ]
    },
    {
      level: 4,
      title: 'Implementing MAT in Practice',
      content: `# Implementing MAT in Clinical Practice

## Getting Started with MAT

### Methadone in OTPs

**Opioid Treatment Program (OTP) requirements:**
- SAMHSA certification
- DEA registration
- State licensing
- Accreditation
- Qualified staff

**Program components:**
- Medical director
- Counseling services
- Drug testing
- Case management
- Dispensing
- Take-home schedules

### Buprenorphine in Office-Based Settings

**DATA-Waiver (X-waiver) requirements:**
- Complete training (8 or 24 hours)
- Apply for waiver
- Prescribe in qualified setting
- Follow patient limits
- Complete ongoing education

**Patient limits (as of 2023):**
- 27 patients in first year
- 100 patients after one year
- 275 patients if additionally qualified
- Limits being phased out (check current rules)

**Practice requirements:**
- Ability to refer for counseling
- Monitor patients
- Check PDMP
- Drug testing
- Maintain records

## Patient Assessment

### Initial Evaluation

**Comprehensive assessment:**

\`\`\'
Substance use history:
    - Age of first use
    - Pattern of use
    - Previous treatments
    - Previous overdoses

Medical history:
    - Co-occurring conditions
    - Liver disease
    - Pain issues
    - Medicications

Psychiatric assessment:
    - Co-occurring disorders
    - Suicide risk
    - Trauma history

Social assessment:
    - Living situation
    - Support system
    - Legal issues
    - Employment

Physical examination:
    - Vital signs
    - Signs of opioid use
    - Medical problems

Laboratory testing:
    - Urine drug screen
    - Liver function tests
    - Hepatitis/HIV testing
    - Pregnancy test
\`\`\'

### Risk Stratification

**Factors for medication selection:**
- Pregnancy status
- Liver function
- Kidney function
- Pain management needs
- Previous treatment response
- Patient preference
- Access to treatment
- Stigma concerns
- Cost/insurance

## Induction Protocols

### Methadone Induction

**Day 1:**
\`\`\'
Assess patient
    ↓
Estimate recent opioid use
    ↓
Starting dose: 10-30mg (individualized)
    ↓
Observe for 2-4 hours
    ↓
Additional 5-10mg if withdrawal persists
    ↓
Maximum day 1: 40mg (federal guidelines)
    ↓
Reassess next day
\`\`\'

**Days 2-7:**
\`\`\'
Assess overnight symptoms
    ↓
Assess for intoxication
    ↓
Adjust dose by 5-10mg
    ↓
Goal: Comfort without intoxication
    ↓
Stabilization typically at 60-120mg
\`\`\'

**Principles:**
- Start low, go slow
- Assess for intoxication
- Assess for withdrawal
- Individualize dose
- Monitor for side effects

### Buprenorphine Induction

**Preparation:**
\`\`\'
Verify patient is in withdrawal
    ↓
COWS score ≥ 8
    ↓
Patient reports feeling withdrawal
    ↓
Objective signs of withdrawal
\`\`\`

**Day 1:**
\`\`\'
Starting dose: 2-8mg (under tongue)
    ↓
Wait 60-90 minutes
    ↓
Assess response
    ↓
Additional 2-4mg if needed
    ↓
Wait another 60-90 minutes
    ↓
Additional 2-4mg if needed
    ↓
Maximum day 1: 8-16mg (some protocols 32mg)
\`\`\`

**Day 2:**
\`\`\'
Assess overnight symptoms
    ↓
Assess patient comfort
    ↓
Adjust dose as needed
    ↓
Target: 8-24mg
\`\`\'

**Principles:**
- Must be in withdrawal first
- Start low, go slow
- Reassess frequently
- Don't rush
- Monitor for precipitated withdrawal

**Avoiding precipitated withdrawal:**
- Verify withdrawal before first dose
- Don't start too soon
- Start with low doses
- Have naloxone available

## Maintenance Treatment

### Ongoing Management

**Regular follow-up:**
\`\`\'
Frequency based on stability:
    - Unstable: Weekly
    - Improving: Biweekly
    - Stable: Monthly
\`\`\'

**At each visit:**
- Assess symptoms
- Check urine drug screen
- Assess cravings
- Monitor side effects
- Review treatment progress
- Adjust dose if needed
- Address psychosocial needs

### Dose Optimization

**Finding the right dose:**
\`\`\'
Goal: Dose that eliminates withdrawal and cravings
    ↓
Without causing intoxication
    ↓
Allows normal functioning
    ↓
Individualized (not one size fits all)
\`\`\'

**Signs dose too low:**
- Withdrawal symptoms
- Cravings
- Continued opioid use
- Poor sleep

**Signs dose too high:**
- Sedation
- Slurred speech
- Small pupils
- Nodding off
- Constipation

### Treatment Goals

**Goals of MAT:**
- Eliminate illicit opioid use
- Reduce or eliminate cravings
- Improve physical and mental health
- Improve social functioning
- Improve quality of life
- Retain patient in treatment
- Prevent overdose

### Behavioral Health Integration

**Counseling should be:**
- Integrated with medication
- Evidence-based
- Individualized
- Culturally competent
- Accessible

**Types of counseling:**
- Cognitive Behavioral Therapy (CBT)
- Motivational Enhancement Therapy (MET)
- 12-Step facilitation
- Contingency Management
- Family therapy
- Group therapy

### Adjunctive Treatments

**For co-occurring conditions:**
- Depression: Antidepressants
- Anxiety: Anxiolytics (caution with benzos)
- PTSD: Trauma-focused therapies
- Insomnia: Sleep hygiene, medications
- Pain: Non-opioid treatments

## Monitoring and Follow-Up

### Drug Testing

**Urine drug screens:**
\`\`\'
Frequency based on stability:
    - Unstable: Weekly
    - Improving: Every 2-4 weeks
    - Stable: Monthly
\`\`\'

**What to test for:**
- Opioids (confirm type)
- Methadone or buprenorphine
- Other substances
- Monitoring adherence

### Laboratory Monitoring

**Methadone:**
- ECG at baseline and high doses (QT monitoring)
- LFTs if liver disease risk

**Buprenorphine:**
- LFTs if liver disease risk
- Consider if symptoms

**Naltrexone:**
- LFTs at baseline and periodically
- Pregnancy testing if indicated

### PDMP Checks

**Prescription Drug Monitoring Program:**
- Check before prescribing
- Check regularly
- Identify risky combinations
- Identify doctor shopping

## Managing Special Situations

### Pregnancy

**Management:**
\`\`\'
Confirm pregnancy
    ↓
Start or continue MAT
    ↓
Methadone: Treatment of choice
    ↓
Buprenorphine: Alternative
    ↓
Avoid naltrexone
    ↓
Coordinate with prenatal care
    ↓
Educate about neonatal abstinence syndrome (NAS)
\`\`\`

### Pain Management

**Challenges:**
- Patients on MAT may have pain
- MAT medications may provide partial pain relief
- Additional pain management often needed

**Approach:**
\`\`\'
Assess pain
    ↓
Non-opioid treatments first
    ↓
Buprenorphine may help (has pain relief properties)
    ↓
Methadone may help
    ↓
Specialist pain management if needed
    ↓
Avoid additional opioids if possible
\`\`\`

### Dental Procedures

**Considerations:**
- Buprenorphine has higher affinity than most opioids
- Regular opioids may not provide pain relief
- May need higher doses or different approach
- Plan with dentist and addiction specialist

### Surgery

**Planning:**
- Continue MAT throughout
- Coordinate with surgeon and anesthesiologist
- May need additional pain medication
- Higher doses often needed
- MAT should be continued

## Legal and Regulatory Considerations

### Federal Regulations

**42 CFR Part 8 (OTPs):**
- Methadone dispensing rules
- Take-home schedules
- Record keeping
- Reporting requirements

**DATA-Waiver Act:**
- Buprenorphine prescribing
- Training requirements
- Patient limits
- Record keeping

### State Regulations

**Vary by state:**
- May be more restrictive than federal
- Additional requirements
- Different forms
- Different reporting

### Confidentiality

**42 CFR Part 2:**
- Confidentiality of substance use disorder records
- Specific consent requirements
- Limits on information sharing
- Recent changes allow more coordination with healthcare

## Quality Improvement

### Metrics

**Process measures:**
- Induction success
- Retention in treatment
- Dose optimization
- Drug testing completion
- Counseling engagement

**Outcome measures:**
- Illicit opioid use
- Overdose events
- Healthcare utilization
- Employment
- Legal issues
- Quality of life
- Mortality

### Improving Outcomes

**Best practices:**
- Rapid access to treatment
- Adequate dosing
- Duration of treatment
- Co-occurring disorder treatment
- Recovery support services
- Relapse prevention
- Overdose education and naloxone`,

      keyPoints: [
        'Buprenorphine requires DATA-Waiver to prescribe in office settings',
        'Induction protocols differ for methadone vs. buprenorphine',
        'Ongoing monitoring includes drug testing and symptom assessment',
        'Integration with behavioral health improves outcomes'
      ],
      vocabulary: [
        { term: 'DATA-Waiver', definition: 'Required training for providers to prescribe buprenorphine in office' },
        { term: 'OTP', definition: 'Opioid Treatment Program - specialized clinic licensed to dispense methadone' },
        { term: 'PDMP', definition: 'Prescription Drug Monitoring Program - tracks controlled substance prescriptions' },
        { term: 'Induction', definition: 'Process of starting patient on MAT medication' }
      ]
    },
    {
      level: 5,
      title: 'Advanced Topics in MAT',
      content: `# Advanced Topics in Medication-Assisted Treatment

## Duration of Treatment

### How Long Should MAT Continue?

**The question of duration:**

\`\`\'
Historical view: MAT is temporary, taper off
Current view: MAT is often long-term or lifelong
\`\`\'

### Evidence for Duration

**Long-term treatment benefits:**
- Reduced mortality
- Reduced illicit opioid use
- Better retention in treatment
- Improved social functioning
- Reduced criminal activity

**Premature discontinuation risks:**
- High relapse rates (50-90%)
- Overdose risk
- Loss of tolerance
- Return to previous use patterns

### When is Long-Term or Lifelong Treatment Indicated?

**Consider long-term/lifelong if:**
- Multiple previous treatment failures
- Severe, chronic OUD
- High overdose risk
- Co-occurring severe mental illness
- Structural brain changes
- Patient preference for continued treatment

**When might tapering be considered:**
- Stable recovery for extended period (1+ years)
- Strong support system
- Life stability
- Patient preference
- Understanding relapse risk

### Tapering Protocols

**If tapering is chosen:**

\`\`\'
Principles:
    - Very slow taper (months to years)
    - Monitor for withdrawal and cravings
    - Restart if relapse occurs
    - Not appropriate for everyone
    - Shared decision-making
\`\`\'

**Methadone taper:**
\`\`\'
Reduce by 5mg every 1-4 weeks
    ↓
Slower as dose decreases
    ↓
May take months to years
    ↓
Monitor closely
\`\`\`

**Buprenorphine taper:**
\`\`\'
Reduce by 2-4mg every 1-4 weeks
    ↓
Slower as dose decreases
    ↓
May take months
    ↓
Monitor closely
\`\`\'

**Naltrexone:**
- Usually stopped abruptly if desired
- No withdrawal
- Overdose risk if opioids used

## Special Populations Revisited

### Adolescents and MAT

**Evidence:**
- Opioid use increasing in adolescents
- MAT effective and appropriate
- Buprenorphine approved for 16+
- Special considerations needed

**Approach:**
- Comprehensive assessment
- Family involvement
- Developmentally appropriate treatment
- Age-appropriate groups
- School collaboration
- Consider longer treatment duration

### Older Adults and MAT

**Unique aspects:**
- May have longer OUD duration
- More medical comorbidities
- More medications (interactions)
- May be iatrogenic (pain medications)
- Atypical presentation possible

**Approach:**
- Lower starting doses
- Slower titration
- More frequent monitoring
- Consider renal/hepatic function
- Polypharmacy review
- Fall risk assessment

### Healthcare Professionals with OUD

**Special considerations:**
- Access to medications
- Monitoring programs
- Career implications
- Stigma
- Legal issues

**Treatment approaches:**
- Specialized treatment programs for healthcare professionals
- Monitoring programs
- Confidentiality concerns
- Career preservation possible
- Long-term monitoring

### People with Pain and OUD

**Complex relationship:**
\`\`\'
Pain → Opioid prescribed → Physical dependence
    ↓
Continued use → Addiction
    ↓
Need both pain treatment and addiction treatment
\`\`\'

**Distinguishing features:**

| Feature | Pseudoaddiction | Addiction |
|---------|----------------|-----------|
| Primary issue | Under-treated pain | Compulsive use |
| Control | Lost control | Maintains control |
| Consequences | Improves with pain control | Continues despite harm |
| Cravings | Not prominent | Prominent |
| Time to relief | With opioids | Brief with opioids |

**Treatment approaches:**

\`\`\'
Integrated pain and addiction treatment:
    - Continue MAT for OUD
    - Non-opioid pain treatments
    - Coordinate with pain specialist
    - Buprenorphine may help with pain
    - Consider higher doses for pain
    - Avoid additional opioids if possible
\`\`\'

**Non-opioid pain management:**
- Physical therapy
- Acupuncture
- Medications (gabapentin, SNRIs, TCAs)
- Interventional procedures
- Cognitive-behavioral approaches
- Mindfulness-based stress reduction

## Co-occurring Disorders

### Mental Illness and OUD

**High co-occurrence:**
- Depression: 40-60%
- Anxiety: 30-50%
- PTSD: 30-40%
- Bipolar: 10-20%
- Psychotic disorders: 5-10%

**Treatment principles:**
- Integrated treatment
- Simultaneous treatment of both disorders
- Medications for both conditions
- Coordination between providers
- Monitoring for interactions

**Special considerations:**

\`\`\'
MAT medications are generally safe with psychiatric medications
    ↓
Monitor for:
    - Interactions
    - Worsening psychiatric symptoms
    - Side effects
    - Adherence
\`\`\'

### Benzodiazepine Co-Prescribing

**The challenge:**
- Common in OUD patients
- Significant overdose risk when combined
- Difficult to discontinue

**Risks of combination:**
- Respiratory depression (especially with methadone)
- Overdose
- Cognitive impairment
- Falls (especially older adults)

**Approach:**
- Avoid combination if possible
- If necessary:
  - Use lowest effective dose
  - Warn about risks
  - Monitor closely
  - Consider buprenorphine (safer than methadone)
  - Taper benzos when possible

## Pharmacogenomics of MAT

### Individual Variation

**Genetic factors affecting:**

\`\`\'
Opioid metabolism genes (CYP450 system)
    ↓
Affects:
    - Methadone metabolism
    - Buprenorphine metabolism
    - Dose requirements
    - Side effects
\`\`\`

**OPRM1 (mu-opioid receptor):**
- Gene variants affect response to medications
- May affect buprenorphine response
- May affect naltrexone response

**Future directions:**
- Genetic testing to guide treatment
- Personalized dosing
- Predicting response
- Not yet standard of care

## Stigma and MAT

### Sources of Stigma

**Common stigmatizing beliefs:**
- "Trading one addiction for another"
- "Not really in recovery"
- "Taking the easy way out"
- "Weak" or "moral failing"

### Addressing Stigma

**Education:**
- MAT as treatment for brain disease
- Comparison to other medical conditions
- Evidence of effectiveness
- Recovery is about health and function

**Language matters:**
- Person-first language
- Avoid stigmatizing terms
- "Medication-assisted recovery"
- "Ongoing treatment"

### Provider Stigma

**Barriers:**
- Lack of knowledge about MAT
- Belief patients don't want it
- Concerns about diversion
- Time constraints
- Regulatory burdens

**Overcoming provider stigma:**
- Education
- Training
- Exposure to successful patients
- Understanding evidence
- Seeing positive outcomes

## Community-Based MAT

### Expanding Access

**Models of care:**

**Primary care integration:**
- MAT in primary care settings
- Collaborative care
- Team-based approach
- Increased access

**Community health centers:**
- FQHCs providing MAT
- Underserved populations
- Integrated care
- Outreach

**Rural health:**
- Telemedicine
- Outreach services
- Collaboration with local providers
- Transportation assistance

### Harm Reduction and MAT

**Overdose prevention:**
\`\`\'
MAT reduces overdose risk by 50%+
    ↓
Additional harm reduction:
    - Naloxone distribution
    - Education
    - Syringe services
    - Safe consumption sites
\`\`\`

**Harm reduction principles:**
- Meet people where they are
- Reduce harms
- Not requiring abstinence
- Evidence-based

## Policy and Public Health

### Effective Policies

**Expanding access:**
- Remove barriers to buprenorphine prescribing
- Increase OTP capacity
- Insurance coverage mandates
- Medicaid coverage
- Parity laws

### Criminal Justice and MAT

**Incarcerated populations:**
- Provide MAT during incarceration
- Continue after release
- Reduce overdose deaths after release
- Improve outcomes

**Drug courts:**
- Encourage MAT participation
- Treatment instead of incarceration
- Improved outcomes

## Future Directions

### Novel Medications

**Under development:**
- New formulations
- New delivery systems
- Combination products
- Extended-duration options

### Personalized Medicine

**Tailoring treatment:**
- Genetics
- Biomarkers
- Previous response
- Comorbid conditions
- Patient preferences

### Technology Integration

**Digital health:**
- Mobile apps for support
- Telemedicine
- Remote monitoring
- Just-in-time interventions
- Digital therapeutics

### Recovery-Oriented Systems of Care

**Comprehensive approach:**
- MAT as one component
- Recovery support services
- Peer support
- Housing assistance
- Employment services
- Family support
- Community integration

## Measuring Success

### Outcomes Beyond Abstinence

**Multiple dimensions:**
- Physical health
- Mental health
- Social functioning
- Employment/education
- Legal involvement
- Quality of life
- Personal growth

### Recovery Definitions

\`\`\'
Multiple pathways to recovery:
    - Abstinence-based
    - Medication-assisted
    - Harm reduction
    - Faith-based
    - Cultural approaches
\`\`\`

**All valid approaches should be supported**`,

      keyPoints: [
        'Long-term or lifelong MAT is often indicated for severe OUD',
        'Tapering should be very slow and only when stable',
        'Co-occurring disorders require integrated treatment',
        'Harm reduction approaches complement MAT'
      ],
      vocabulary: [
        { term: 'Iatrogenic', definition: 'Caused by medical treatment or examination' },
        { term: 'Pseudoaddiction', definition: 'Behaviors resembling addiction caused by under-treated pain' },
        { term: 'Pharmacogenomics', definition: 'Study of how genes affect medication response' },
        { term: 'Recovery Capital', definition: 'Resources supporting recovery' }
      ]
    }
  ]
};
